Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates and working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Prenatal and new-born genetic testing industry 3600 synopsis, 2016 - 2027
2.1.1 Business trends
2.1.2 Technology trends
2.1.3 Disease trends
2.1.4 End-use trends
2.1.5 Regional trends
Chapter 3 Prenatal and New-born Genetic Testing Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2016 – 2027 (USD Million)
3.3 Industry impact factors
3.3.1 Growth drivers
3.3.1.1 Technological advancements and increasing benefits in the field of prenatal testing and new-born genetic screening
3.3.1.2 Increasing prevalence of genetic disorders and chromosomal abnormalities
3.3.1.3 Rising consanguineous relations
3.3.1.4 Government initiatives and support for prenatal testing and new-born genetic screening
3.3.1.5 Rise in adoption of Non-invasive Prenatal Testing
3.3.2 Industry pitfalls and challenges
3.3.2.1 Increasing false results for prenatal tests
3.3.2.2 Lack of advanced infrastructure and skilled labor
3.3.2.3 Ethical issues to prenatal testing and new-born genetic screening
3.4 Growth potential analysis
3.4.1 By technology
3.4.2 By disease
3.4.3 By end-use
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Porter’s analysis
3.8 Competitive landscape, 2020
3.8.1 Company matrix analysis, 2020
3.9 PESTEL analysis
Chapter 4 Prenatal and New-born Genetic Testing Market, By Technology
4.1 Key segment trends
4.2 Screening
4.2.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.2 Chorionic Villus Sampling
4.2.2.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.3 Maternal Serum Screening
4.2.3.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.4 Amniocentesis
4.2.4.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.5 Non-invasive Prenatal Testing
4.2.5.1 Market size, by region, 2016 – 2027 (USD Million)
4.2.6 Others
4.2.6.1 Market size, by region, 2016 - 2027 (USD Million)
4.3 Diagnostic
4.3.1 Market size, by region, 2016 – 2027 (USD Million)
4.3.2 mmPCR
4.3.2.1 Market size, by region, 2016 - 2027 (USD Million)
4.3.3 Spectrophotometer
4.3.3.1 Market size, by region, 2016 - 2027 (USD Million)
4.3.4 FISH
4.3.4.1 Market size, by region, 2016 - 2027 (USD Million)
4.3.5 Assays
4.3.5.1 Market size, by region, 2016 - 2027 (USD Million)
4.3.6 Others
4.3.6.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 5 Prenatal and New-born Genetic Testing Market, By Disease
5.1 Key segment trends
5.2 Down’s Syndrome
5.2.1 Market size, by region, 2016 - 2027 (USD Million)
5.3 Phenylketonuria
5.3.1 Market size, by region, 2016 - 2027 (USD Million)
5.4 Cystic Fibrosis
5.4.1 Market size, by region, 2016 - 2027 (USD Million)
5.5 Sickle Cell Anaemia
5.5.1 Market size, by region, 2016 - 2027 (USD Million)
5.6 Others
5.6.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 6 Prenatal and New-born Genetic Testing Market, By End-use
6.1 Key segment trends
6.2 Hospitals
6.2.1 Market size, by region, 2016 – 2027 (USD Million)
6.3 Maternity and Specialty Clinics
6.3.1 Market size, by region, 2016 – 2027 (USD Million)
6.4 Diagnostic Centers
6.4.1 Market size, by region, 2016 - 2027 (USD Million)
Chapter 7 Prenatal and New-born Genetic Testing Market, By Region
7.1 Key regional trends
7.2 North America
7.2.1 Market size, by country, 2016 - 2027 (USD Million)
7.2.2 Market size, by technology, 2016 - 2027 (USD Million)
7.2.2.1 Market size, by screening, 2016 - 2027 (USD Million)
7.2.2.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.2.3 Market size, by disease, 2016 - 2027 (USD Million)
7.2.4 Market size, by end-use, 2016 – 2027 (USD Million)
7.2.5 U.S.
7.2.5.1 Market size, by technology, 2016 - 2027 (USD Million)
7.2.5.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.2.5.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.2.5.2 Market size, by disease, 2016 - 2027 (USD Million)
7.2.5.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.2.6 Canada
7.2.6.1 Market size, by technology, 2016 - 2027 (USD Million)
7.2.6.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.2.6.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.2.6.2 Market size, by disease, 2016 - 2027 (USD Million)
7.2.6.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.3 Europe
7.3.1 Market size, by country, 2016 - 2027 (USD Million)
7.3.2 Market size, by technology, 2016 - 2027 (USD Million)
7.3.2.1 Market size, by screening, 2016 - 2027 (USD Million)
7.3.2.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.3.3 Market size, by disease, 2016 - 2027 (USD Million)
7.3.4 Market size, by end-use, 2016 – 2027 (USD Million)
7.3.5 Germany
7.3.5.1 Market size, by technology, 2016 - 2027 (USD Million)
7.3.5.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.3.5.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.3.5.2 Market size, by disease, 2016 - 2027 (USD Million)
7.3.5.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.3.6 UK
7.3.6.1 Market size, by technology, 2016 - 2027 (USD Million)
7.3.6.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.3.6.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.3.6.2 Market size, by disease, 2016 - 2027 (USD Million)
7.3.6.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.3.7 France
7.3.7.1 Market size, by technology, 2016 - 2027 (USD Million)
7.3.7.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.3.7.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.3.7.2 Market size, by disease, 2016 - 2027 (USD Million)
7.3.7.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.3.8 Italy
7.3.8.1 Market size, by technology, 2016 - 2027 (USD Million)
7.3.8.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.3.8.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.3.8.2 Market size, by disease, 2016 - 2027 (USD Million)
7.3.8.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.3.9 Spain
7.3.9.1 Market size, by technology, 2016 - 2027 (USD Million)
7.3.9.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.3.9.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.3.9.2 Market size, by disease, 2016 - 2027 (USD Million)
7.3.9.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.4 Asia Pacific
7.4.1 Market size, by country, 2016 - 2027 (USD Million)
7.4.2 Market size, by technology, 2016 - 2027 (USD Million)
7.4.2.1 Market size, by screening, 2016 - 2027 (USD Million)
7.4.2.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.4.3 Market size, by disease, 2016 - 2027 (USD Million)
7.4.4 Market size, by end-use, 2016 – 2027 (USD Million)
7.4.5 China
7.4.5.1 Market size, by technology, 2016 - 2027 (USD Million)
7.4.5.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.4.5.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.4.5.2 Market size, by disease, 2016 - 2027 (USD Million)
7.4.5.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.4.6 India
7.4.6.1 Market size, by technology, 2016 - 2027 (USD Million)
7.4.6.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.4.6.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.4.6.2 Market size, by disease, 2016 - 2027 (USD Million)
7.4.6.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.4.7 Japan
7.4.7.1 Market size, by technology, 2016 - 2027 (USD Million)
7.4.7.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.4.7.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.4.7.2 Market size, by disease, 2016 - 2027 (USD Million)
7.4.7.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.4.8 Australia
7.4.8.1 Market size, by technology, 2016 - 2027 (USD Million)
7.4.8.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.4.8.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.4.8.2 Market size, by disease, 2016 - 2027 (USD Million)
7.4.8.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.5 Latin America
7.5.1 Market size, by country, 2016 - 2027 (USD Million)
7.5.2 Market size, by technology, 2016 - 2027 (USD Million)
7.5.2.1 Market size, by screening, 2016 - 2027 (USD Million)
7.5.2.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.5.3 Market size, by disease, 2016 - 2027 (USD Million)
7.5.4 Market size, by end-use, 2016 – 2027 (USD Million)
7.5.5 Brazil
7.5.5.1 Market size, by technology, 2016 - 2027 (USD Million)
7.5.5.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.5.5.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.5.5.2 Market size, by disease, 2016 - 2027 (USD Million)
7.5.5.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.5.6 Mexico
7.5.6.1 Market size, by technology, 2016 - 2027 (USD Million)
7.5.6.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.5.6.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.5.6.2 Market size, by disease, 2016 - 2027 (USD Million)
7.5.6.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.5.7 Argentina
7.5.7.1 Market size, by technology, 2016 - 2027 (USD Million)
7.5.7.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.5.7.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.5.7.2 Market size, by disease, 2016 - 2027 (USD Million)
7.5.7.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.6 Middle East and Africa
7.6.1 Market size, by country, 2016 - 2027 (USD Million)
7.6.2 Market size, by technology, 2016 - 2027 (USD Million)
7.6.2.1 Market size, by screening, 2016 - 2027 (USD Million)
7.6.2.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.6.3 Market size, by disease, 2016 - 2027 (USD Million)
7.6.4 Market size, by end-use, 2016 – 2027 (USD Million)
7.6.5 South Africa
7.6.5.1 Market size, by technology, 2016 - 2027 (USD Million)
7.6.5.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.6.5.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.6.5.2 Market size, by disease, 2016 - 2027 (USD Million)
7.6.5.3 Market size, by end-use, 2016 – 2027 (USD Million)
7.6.6 Saudi Arabia
7.6.6.1 Market size, by technology, 2016 - 2027 (USD Million)
7.6.6.1.1 Market size, by screening, 2016 - 2027 (USD Million)
7.6.6.1.2 Market size, by diagnostic, 2016 - 2027 (USD Million)
7.6.6.2 Market size, by disease, 2016 - 2027 (USD Million)
7.6.6.3 Market size, by end-use, 2016 – 2027 (USD Million)
Chapter 8 Company Profiles
8.1 Competitive dashboard, 2020
8.2 Abbott
8.2.1 Business overview
8.2.2 Financial data
8.2.3 Technology landscape
8.2.4 Strategic outlook
8.2.5 SWOT analysis
8.3 Agilent
8.3.1 Business overview
8.3.2 Financial data
8.3.3 Technology landscape
8.3.4 Strategic outlook
8.3.5 SWOT analysis
8.4 AutoGenomics
8.4.1 Business overview
8.4.2 Financial data
8.4.3 Technology landscape
8.4.4 Strategic outlook
8.4.5 SWOT analysis
8.5 Ariosa Diagnostics
8.5.1 Business overview
8.5.2 Financial data
8.5.3 Technology landscape
8.5.4 Strategic outlook
8.5.5 SWOT analysis
8.6 Baebies
8.6.1 Business overview
8.6.2 Financial data
8.6.3 Technology landscape
8.6.4 Strategic outlook
8.6.5 SWOT analysis
8.7 Berry Genomics Co. Ltd
8.7.1 Business overview
8.7.2 Financial data
8.7.3 Technology landscape
8.7.4 Strategic outlook
8.7.5 SWOT analysis
8.8 BGI
8.8.1 Business overview
8.8.2 Financial data
8.8.3 Technology landscape
8.8.4 Strategic outlook
8.8.5 SWOT analysis
8.9 Biocartis Group NV
8.9.1 Business overview
8.9.2 Financial data
8.9.3 Technology landscape
8.9.4 Strategic outlook
8.9.5 SWOT analysis
8.10 Bio-Rad Laboratories, Inc.
8.10.1 Business overview
8.10.2 Financial data
8.10.3 Technology landscape
8.10.4 Strategic outlook
8.10.5 SWOT analysis
8.11 Illumina, Inc
8.11.1 Business overview
8.11.2 Financial data
8.11.3 Technology landscape
8.11.4 Strategic outlook
8.11.5 SWOT analysis
8.12 Laboratory Corporation of America
8.12.1 Business overview
8.12.2 Financial data
8.12.3 Technology landscape
8.12.4 Strategic outlook
8.12.5 SWOT analysis
8.13 Masimo Corporation
8.13.1 Business overview
8.13.2 Financial data
8.13.3 Technology landscape
8.13.4 Strategic outlook
8.13.5 SWOT analysis
8.14 Natera, Inc.
8.14.1 Business overview
8.14.2 Financial data
8.14.3 Technology landscape
8.14.4 Strategic outlook
8.14.5 SWOT analysis
8.15 PerkinElmer, Inc
8.15.1 Business overview
8.15.2 Financial data
8.15.3 Technology landscape
8.15.4 Strategic outlook
8.15.5 SWOT analysis
8.16 Progenity, Inc.
8.16.1 Business overview
8.16.2 Financial data
8.16.3 Technology landscape
8.16.4 Strategic outlook
8.16.5 SWOT analysis
8.17 Qiagen
8.17.1 Business overview
8.17.2 Financial data
8.17.3 Technology landscape
8.17.4 Strategic outlook
8.17.5 SWOT analysis
8.18 Sequenom, Inc.
8.18.1 Business overview
8.18.2 Financial data
8.18.3 Technology landscape
8.18.4 Strategic outlook
8.18.5 SWOT analysis
8.19 Trivitron Healthcare Private Limited
8.19.1 Business overview
8.19.2 Financial data
8.19.3 Technology landscape
8.19.4 Strategic outlook
8.19.5 SWOT analysis
